EVO756 for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new medication, EVO756, to evaluate its effectiveness and safety in treating moderate to severe eczema (also known as atopic dermatitis). Participants will receive one of three different doses of EVO756 or a placebo (a pill with no active medication) for comparison. Individuals who have experienced eczema for at least six months and have significant body coverage may qualify for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to important advancements in eczema treatment.
Do I need to stop taking my current medications for the trial?
The trial information mentions the exclusion of participants using certain medications, but it doesn't specify which ones. It's best to discuss your current medications with the study team to see if they might affect your eligibility.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that EVO756 has been promising in earlier studies. Researchers have tested it in people with conditions like symptomatic dermographism, a type of skin reaction. In these studies, most participants tolerated EVO756 well, experiencing no serious side effects. While all medications can have some side effects, current data suggest that EVO756 does not present major safety concerns so far. Now in a Phase 2 trial, researchers continue to collect safety information and assess the effectiveness of different doses. This phase ensures the treatment is safe enough before testing it on a larger group.12345
Why do researchers think this study treatment might be promising for eczema?
Researchers are excited about EVO756 for eczema because it offers a potentially new approach to treating this condition. Unlike standard treatments like topical corticosteroids or calcineurin inhibitors, EVO756 is taken orally, which could make it more convenient for patients. Additionally, it may target the underlying inflammation in eczema differently, possibly providing relief for those who do not respond well to current options. This could mean a significant improvement in quality of life for many sufferers.
What evidence suggests that EVO756 might be an effective treatment for eczema?
Research has shown that EVO756, which participants in this trial may receive, may help treat atopic dermatitis, a type of eczema. Studies have found that EVO756 blocks a receptor involved in inflammation and itchiness. This action calms certain cells and nerves, reducing itch and inflammation. In earlier trials, 30% of patients with chronic itchy skin conditions experienced complete relief in just four weeks. These early results suggest EVO756 could effectively manage moderate to severe eczema symptoms.23567
Are You a Good Fit for This Trial?
Adults with moderate to severe atopic dermatitis can join this trial. They should have a chronic condition for over 6 months, affected skin area of at least 10%, and certain severity scores. People with recent significant flares, abnormal lab results, or using excluded medications cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive different doses of EVO756 or placebo to evaluate efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- EVO756
Trial Overview
The study is testing EVO756's effectiveness and safety in different doses compared to a placebo control. It aims to see how well it works for adults with moderate to severe atopic dermatitis.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Orally administered EVO756, Dose 3
Orally administered EVO756, Dose 2
Orally administered EVO756, Dose 1
Placebo control
Find a Clinic Near You
Who Is Running the Clinical Trial?
Evommune, Inc.
Lead Sponsor
Citations
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis. Official Title. A Randomized, ...
Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 ...
The primary objective of this trial is to characterize the efficacy of multiple dose levels of EVO756 compared to placebo as assessed by the ...
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 ...
EVO756 has been observed to deliver modulation on both mast cells and peripheral sensory neurons, representing a new potential therapeutic ...
Chronic Inflammation | MRGPRX2 Antagonist EVO756
In addition, due to its unique function on peripheral sensory neurons, blocking MRGPRX2 could provide fast relief of itch associated with inflammatory diseases, ...
5.
thedermdigest.com
thedermdigest.com/evommunes-evo756-performs-well-in-phase-2-study-of-adults-with-cindu/Evommune's EVO756 Performs Well in Phase 2 Study of ...
Fully 30% of adult chronic inducible urticaria (CIndU) patients achieved a complete response after four weeks of dosing with EVO756.
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis. Official Title. A Randomized, ...
Clinical Trials - Chronic Inflammatory Disease
Participants will receive EVO756 or placebo daily for a 12-week treatment period and be evaluated for safety and efficacy at pre-specified visits at the ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.